Breaking the Daily Routine With Insulin Efsitora Alfa, a Once-Weekly Basal Insulin

Although newer glucose-lowering agents are preferred for their benefits in managing common comorbidities, insulin remains essential as the primary treatment of type 1 diabetes and an important option in the treatment of type 2 diabetes (1). Innovations in insulin molecule design and formulation have led to once-weekly basal insulin candidates such as insulin efsitora alfa (efsitora), which aim to mimic physiological insulin secretion (2). By combining extended duration of action and simplified dosing, efsitora represents a step toward the ideal basal insulin: one that is more physiological, predictable, and patient-friendly.